Inventiva S.A. (EPA:IVA)
2.955
+0.110 (3.87%)
Sep 28, 2026, 5:37 PM CET
Inventiva Revenue
Inventiva had revenue of 1.31M EUR in the half year ending June 30, 2026, a decrease of -52.23%. This brings the company's revenue in the last twelve months to 3.62M, down -75.47% year-over-year. In the year 2025, Inventiva had annual revenue of 7.93M, down -46.17%.
Revenue (ttm)
3.62M
Revenue Growth
-75.47%
P/S Ratio
99.43
Revenue / Employee
92.62K
Employees
77
Market Cap
672.22M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.93M | -6.80M | -46.17% |
| Dec 31, 2024 | 14.72M | -8.44M | -36.43% |
| Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
| Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
| Dec 31, 2018 | 7.38M | -2.58M | -25.90% |
| Dec 31, 2017 | 9.96M | -4.39M | -30.61% |
| Dec 31, 2016 | 14.35M | 5.69M | 65.66% |
| Dec 31, 2015 | 8.66M | 2.36M | 37.55% |
| Dec 31, 2014 | 6.30M | 1.20M | 23.46% |
| Dec 31, 2013 | 5.10M | 5.06M | 10,977.18% |
| Dec 31, 2012 | 46.06K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 142.94M |
| Genfit | 70.85M |
| Cellectis | 55.86M |
| MedinCell | 24.28M |
| Nanobiotix | 11.51M |
| Innate Pharma | 9.81M |
| Transgene | 7.21M |
| Sensorion | 6.16M |
Inventiva News
- 10 hours ago - Inventiva Q2 Earnings Call Highlights - MarketBeat
- 12 hours ago - Inventiva Earnings Call Transcript: Q2 2026 - Transcripts
- 12 hours ago - Inventiva Earnings release: Q2 2026 - Filings
- 12 days ago - Inventiva SA at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
- 13 days ago - Inventiva Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 13 days ago - Inventiva price target raised to $14 from $11 at Guggenheim - TheFly
- 20 days ago - RUBIS: H1 2026 Results - Strong performance leading way to upgrade of 2026 guidance - GlobeNewsWire
- 25 days ago - Inventiva Reports Final Patient Visit In Phase 3 NATiV3 Study For Lanifibranor; Topline Data In Q4 - Nasdaq